Should You Worry About the Latest Wave of Bad News from Pfizer?
Earlier in the pandemic, (NYSE: PFE) stood out as an earnings and stock-market star thanks to its leading coronavirus vaccine and treatment. But these days, those products are weighing on growth -- and pushing some investors to flee the stock. That's because, as we head toward a post-pandemic world, demand for those blockbusters is on the decline.
Earlier this fall, Pfizer sounded the alarm, cutting its forecast for coronavirus product revenue this year and announcing details of a cost-cutting plan. Just this past week, the big pharma released guidance on earnings and coronavirus product revenue for next year that fell short of analysts' expectations. And the company aims to make even deeper cost cuts than initially planned.
Pfizer shares responded by dropping to a 10-year low. Considering this latest wave of bad news, should you worry about Pfizer and avoid the shares -- or is it time to buy?
Source Fool.com
Pfizer Inc. Aktie
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 27.64 € bedeuten.
